Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,678 questions · 4,859 findings · 283 reviews

No studies found 1,225 · 25.2%GRADE not reported 215 · 4.4%Very low 1,241 · 25.5%Low 1,210 · 24.9%Moderate 776 · 16%High 192 · 4%

Summary of findings table (subcomparison 3): chemotherapy agent(s) plus control intervention vs control intervention

Overall survival · palliative participants with esophageal and GE‐junction carcinoma

Summary of findings table (subcomparison 3): chemotherapy agent(s)… probably leads to lower overall survival compared with control intervention alone (moderate certainty).

1 finding from 1 review

Summary of findings table (subcomparison 3): chemotherapy agent(s) plus control intervention vs control intervention

Toxicity · palliative participants with esophageal and GE‐junction carcinoma

It is very uncertain whether summary of findings table (subcomparison 3): chemotherapy agent(s)… changes toxicity compared with control intervention alone (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Intermittent PEG‐asparaginase treatment (8 doses, 1000 IU/m2, IM) vs continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM)

Overall survival ‐ not reported · children and adolescents (< 18 years of age) with first‐line ALL

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings table ‐ Intermittent PEG‐asparaginase treatment (8 doses, 1000 IU/m2, IM) vs continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM)

Event‐free survival · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… showed no clear difference in event‐free survival compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Intermittent PEG‐asparaginase treatment (8 doses, 1000 IU/m2, IM) vs continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM)

Hypersensitivity · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… showed no clear difference in hypersensitivity compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (low certainty).

1 finding from 1 review

Summary of findings table ‐ Intermittent PEG‐asparaginase treatment (8 doses, 1000 IU/m2, IM) vs continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM)

Pancreatitis · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… probably leads to lower pancreatitis compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Intermittent PEG‐asparaginase treatment (8 doses, 1000 IU/m2, IM) vs continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM)

Thromboembolism · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… showed no clear difference in thromboembolism compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (low certainty).

1 finding from 1 review

Summary of findings table ‐ Intermittent PEG‐asparaginase treatment (8 doses, 1000 IU/m2, IM) vs continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM)

Osteonecrosis · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… showed no clear difference in osteonecrosis compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (low certainty).

1 finding from 1 review

Summary of findings table ‐ Intermittent PEG‐asparaginase treatment (8 doses, 1000 IU/m2, IM) vs continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM)

Asparaginase‐associated toxicity · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… probably leads to lower asparaginase‐associated toxicity compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (moderate certainty).

1 finding from 1 review

Summary of findings table (subcomparison 4): targeted therapy agent plus control intervention vs control intervention

Overall survival · palliative participants with esophageal and GE‐junction carcinoma

Summary of findings table (subcomparison 4): targeted therapy agent… leads to lower overall survival compared with control intervention alone (high certainty).

1 finding from 1 review

Summary of findings table (subcomparison 4): targeted therapy agent plus control intervention vs control intervention

Progression‐free survival · palliative participants with esophageal and GE‐junction carcinoma

Summary of findings table (subcomparison 4): targeted therapy agent… probably leads to lower progression‐free survival compared with control intervention alone (moderate certainty).

1 finding from 1 review

Summary of findings table (subcomparison 4): targeted therapy agent plus control intervention vs control intervention

Toxicity · palliative participants with esophageal and GE‐junction carcinoma

It is very uncertain whether summary of findings table (subcomparison 4): targeted therapy agent… changes toxicity compared with control intervention alone (very low certainty).

1 finding from 1 review

Summary of findings table 2: comparison of operation types: late results of needle fasciotomy vs limited fasciectomy

DASH hand function score at 3 months Major outcome group 1 (hand function) (scores between 0 and 100, where 0 represents no impairment in hand function and 100 represents maximum impairment in hand function) · 93 participants (van Rijssen 2012a)

The review found no eligible studies for this question.

1 finding from 1 review